Strategies for the prevention of cytomegalovirus infection and disease in pediatric liver transplantation recipients

Pediatric Transplantation

Volumn 8, Issue 6, 2004, Pages 619-627

  Campbell, Andrew L ^a   Herold, Betsy C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cytomegalovirus; Liver transplant; Pre emptive therapy; Solid organ transplantation; Universal prophylaxis

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CYTOMEGALOVIRUS ANTIBODY; GANCICLOVIR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; VALACICLOVIR; VALGANCICLOVIR;

CLINICAL LABORATORY; CONFERENCE PAPER; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; HUMAN; LIVER TRANSPLANTATION; MOLECULAR BIOLOGY; VIROLOGY;

ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; LIVER TRANSPLANTATION; OPPORTUNISTIC INFECTIONS; POSTOPERATIVE COMPLICATIONS; SENSITIVITY AND SPECIFICITY;

EID: 11144242204     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2004.00242.x     Document Type: Conference Paper

References (75)

1. RUBIN RH. Infection in the renal and liver transplant patient. In: RUBIN RH, YOUNG LS, eds. Clinical Approach to Infection in the Compromised Host, 4th edn. New York: Kluwer/Plenum, 1992: pp: 629-705.
2. GEORGE DL, ARNOW PM, FOX A, et al. Patterns of infection after pediatric liver transplantation. Am J Dis Child 1992: 146: 924-929.
3. HADLEY S, SAMORE MH, LEWIS DW, JENKINS RL, KARCHMER AW, HAMMER SM. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. Transplantation 1995: 59: 851-859.
4. KING SM, PETRIC M, SUPERINA R, GRAHAM N, ROBERTS EA. Cytomegalovirus infections in pediatric liver transplantation. Am J Dis Child 1990: 144: 1307-1310.
5. KANJ S, SHARA A, CLAVIEN P, et al. Cytomegalovirus infection following liver transplantation: review of the literature. Clin Infect Dis 1996: 22: 537.
6. O'GRADY JG, SUTHERLAND S, DONALDSON PT, et al. Cytomegalovirus infection and donor/recipient HLA antigens: Interdependent co-factors in pathogenesis of vanishing bile duct syndrome after liver transplantation. Lancet 1988: 2: 302.
7. ARNOLD JC, PORTMANN BC, O'GRADY JG, et al. Cytomegalovirus infection persists in the liver graft in the vanishing bile duct syndrome. Hepatology 1992: 16: 285.
8. EVANS PC, SOIN A, WREGHITT TG, TAYLOR CJ, WIGHT DGD, ALEXANDER GJM. An association between cytomegalovirus infection and chronic rejection after liver transplantation. Transplantation 2000: 69: 30.
9. GILLINGHAM KJ, PAYNE WD, DUNN DL, SUTHERLAND DER, MATES AJ. Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients. Transplantation 1999: 68: 1879.
10. GEORGE M, SNYDMAN D, WERNER B, et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Am J Med 1997: 103: 106.
11. DE OTERO J, GAVALDA J, MURIO E, et al. Cytomegalovirus disease as a risk factor for graft loss and death after orthotopic liver transplantation. Clin Infect Dis 1998: 26: 865-870.
12. FORD-JONES E, KITAI I, DAVIS L, et al. Cytomegalovirus infections in Toronto child-care centers: a prospective study of viral excretion in children and seroconversion among day-care providers. Pediatr Infect Dis J 1996: 15: 507-514.
13. DOBBINS J, ADLER S, PASS R, et al. The risks and benefits of cytomegalovirus transmission in child day care. Pediatrics 1994: 94: 1016-1018.
14. BREINING M, ZITELLI B, STARZI T, et al. Epstein-Barr virus, cytomegalovirus, and other viral infections in children after liver transplantation. J Infect Dis 1987: 156: 273-279.
15. SYNDMAN DR. Cytomegalovirus prophylaxis strategies in high-risk transplantation. Transplant Proc 1994: 26: 468-474.
16. HUTTO C, RICKS R, GARVIE M, et al. Epidemiology of cytomegalovirus infections in young children: day care vs. home care. Pediatr Infect Dis J 1985: 4: 149-152.
17. COUCHOUD C, CUCHERAT M, HAUGH M, et al. Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation: a meta-analysis. Transplantation 1998: 65: 641-647.
18. RUBIN R. Cytomegalovirus disease and allograft loss after solid organ transplantation. Clin Infect Dis 1998: 26: 871-873.
19. BOWMAN J, GREEN M, SCANTLEBURY V, et al. OKT3 and viral disease in pediatric liver transplant recipients. Clin Transplant 1991: 5: 294-300.
20. DICKINSON B, CORA-HARPER M, MCCRANEY S, et al. Studies evaluating high-dose acyclovir, intravenous immune globulin, and cytomegalovirus hyperimmunoglobulin for prophylaxis against cytomegalovirus in kidney transplant recipients. Ann Pharmacother 1996: 30: 1452-1464.
21. SNYDMAN D, WERNER B, DOUGHTERY J, et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1993: 119: 984-991.
22. GLOWACKI LS, SMAILL FM. Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients - a meta-analysis. Clin Transplant 1994: 8: 10-18.
23. KASISKE B, HEIM-DUTHOY K, TORTORICE A, et al. Polyvalent immune globulin and cytomegalovirus infection after renal transplantation. Arch Intern Med 1989: 149: 2733-2736.
24. CRUMPACKER C. Ganciclovir. N Engl J Med 1996: 335: 721-729.
25. BALFOUR HH, CHACE BA, STAPLETON JT, et al. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989: 320: 1281-1387.
26. BARKHOLT L, LEWENSOHN-FUCJS I, ERICZON B-G, et al. High-dose acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patients. Transpl Infect Dis 1999: 1: 89-97.
27. GAVALDA J, DE OTERO J, VARGAS V, et al. Two grams of oral acyclovir reduces the incidence of cytomegalovirus disease in CMV seropositive liver transplant recipients. Transpl Int 1997: 10: 462-465.
28. COHEN A, O'GRADY G, SUTHERLAND S, et al. Controlled trial of prophylactic versus therapeutic use of ganciclovir in liver transplantation in adults. J Med Virol 1993: 40: 5-9.
29. WINSTON D, WIRIN D, SHAKED A, et al. Randomised comparison of ganciclovir and high dose acyclovir for long-term prophylaxis in liver-transplant recipients. Lancet 1995: 346: 69-74.
30. MARTIN F, MANEZ R, LINDEN D, et al. A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to acyclovir for the prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1994: 58: 779-785.
31. BADLEY A, PATEL R, PORTELA D, et al. Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. Transplantation 1997: 64: 66-73.
32. GREEN M, KAUFMANN M, WILSON J, et al. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation. Clin Infect Dis 1997: 25: 1344-1349.
33. GANE E, SALIBA F, VALDECASEA G, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997: 350: 1729-1733.
34. BRENNEN D, GARLOCK K, SINGER G, et al. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 1997: 64: 1843-1846.
35. PESCOVITZ MD, RABKIN J, MERION RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000: 44: 2811-2815.
36. AKALIN E, SEHGAL V, AMES S, et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 2003: 3: 731-735.
37. PAYA CV. A randomized, double-blind, double-dummy, active-comparator controlled multi-center study of the efficacy and safety of valganciclovir vs oral ganciclovir for prevention of CMV disease in 372 high-risk (D+ /R-) heart liver and kidney recipients. Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego, CA, USA (Abstract LB-4).
38. BOIVIN G, GOYETTE N, GILBERT C, et al. Low frequency of emergence of cytomegalovirus UL97 mutations associated with ganciclovir resistance in solid organ transplant patients receiving valganciclovir or oral ganciclovir prophylaxis. Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego, California (Abstract V-1248).
39. DUNCAN S, GRGURICH W, IACONO A, et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med 1994: 150: 146-152.
40. LIMAYE AP, COREY L, KOELLE DM, et al. Emergence of ganciclovir-resistant cytomegalovirus disease among solid-organ transplants. Lancet 2000: 356: 645-649.
41. LOWANCE D, NEUMAYER H-H, LEGENDRE C, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999: 340: 1462-1470.
42. RUBIN R. Preemptive therapy in immunocompromised hosts. N Engl J Med 1991: 324: 1057-1059.
43. PATEL R, SNYDMAN D, RUBIN R, et al. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 1996: 61: 1279-1289.
44. RUBIN R. Antimicrobial strategies in the care of organ transplant recipients. Antimicrob Agents Chemother 1993: 37: 619-624.
45. SIA I, PATEL R. New Strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev 2000: 13: 83-121.
46. SCHMIDT GM, HORAK DA, NILAND J, et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogenic bone marrow transplants. N Engl J Med 1991: 324: 1005-1011.
47. PERIS J, TAYLOR C, MAIN J, et al. Diagnosis of cytomegalovirus (CMV) disease in renal allograft recipients: the role of semi-quantitative polymerase chain reaction (PCR). Nephrol 1995: 10: 1198-1205.
48. TANABE K, TOKUMOTO T, ISHIKAWA N, et al. Comparative study of cytomegalovirus (CMV) antigenemia assay, polymerase chain reaction, serology, and shell viral assay in the early diagnosis and monitoring of CMV infection after renal transplantation. Transplantation 1997: 64: 1721-1725.
49. EGAN J, BARBER L, LOMAX J, et al. Detection of human cytomegalovirus antigenaemia: a rapid diagnostic technique for predicting cytomegalovirus infection/pneumonitis in lung and heart transplant recipients. Thorax 1995: 50: 9-13.
50. IBERER F, TSCHELIESSNIGG G, HALWACHS G, et al. Definitions of cytomegalovirus disease after heart transplantation: antigenemia as a marker for antiviral therapy. Transplant Int 1996: 9: 236-242.
51. TONO C, CUEVAS L, WILLIAMS H, et al. Use of laboratory assays to predict cytomegalovirus disease in renal transplant recipients. J Clin Microbiol 1998: 36: 2681-2685.
52. KOSKINEN P, NIEMINEN S, MARRILA S, et al. The correlation between symptomatic CMV infection and CMV antigenemia in heart allograft recipients. Transplantation 1993: 55: 547-551.
53. EGAN J, LOMAX J, BARBER L, et al. Preemptive treatment for the prevention of cytomegalovirus disease in lung and heart transplant recipients. Transplantation 1997: 65: 747-752.
54. GOTTI E, SUTER F, BARUZZO S, et al. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia. Clin Transplant 1996: 10: 550-555.
55. KUSNE S, GROSSI P, IRISH W, et al. Cytomegalovirus pp65 antigenemia monitoring as a guide for pre-emptive therapy: a cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1999: 68: 1125-1131.
56. ABECASSIA M, KOFFRON A, KAPLAN B, et al. The role of PCR in the diagnosis and management of CMV in solid organ recipients: what is the predictive value for the development of disease and should PCR be used to guide antiviral therapy? Transplantation 1997: 63: 275-279.
57. MENDEZ J, ESPY M, SMITH T, et al. Clinical significance of viral load in the diagnosis of cytomegalovirus disease after liver transplantation. Transplantation 1998: 65: 1477-1481.
58. NORRIS S, KOSAR Y, DONALDSON N, et al. Cytomegalovirus infection after liver transplantation: viral load as a guide to treating clinical infection. Transplantation 2002: 74: 527-531.
59. PAYA C, WILSON J, ESPY M, et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis 2002: 185: 854-860.
60. WOLFF C, SKOURTOPOULOS M, HORNSCHEMEYER D, et al. Significance of human cytomegalovirus DNA detection in immunocompromised heart transplant patients. Transplantation 1996: 61: 750-757.
61. MENDEZ J, ESPY M, SMITH T, et al. Evaluation of PCR primers for early diagnosis of cytomegalovirus infection following liver transplantation. J Clin Microbiol 1998: 36: 526-530.
62. EGAN J, LOMAX J, BARBER L, et al. Preemptive treatment for the prevention of cytomegalovirus disease. Transplantation 1998: 65: 1125-1131.
63. BOECKH M, GOOLEY T, MYERSON D, et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind trial. Blood 1996: 88: 4063-4071.
64. SINGH N, PATERSON DL, GAYOWSKI T, et al. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, controlled trial. Transplantation 2000: 70: 717-722.
65. SINGH N. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clin Infect Dis 2001: 32: 742-751.
66. TORRE-CISNEROS J, MADUENO J, GONZALEZ R, et al. Preemptive therapy with oral ganciclovir of cytomegalovirus disease in liver transplant recipients monitored with plasma PCR and leucocyte viral load [abstract H59a]. In Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA: American Society for Microbiology, 1997: pp: 224.
67. CHOU S, MAROUSEK G, GUENTZEL S, et al. Evolution of mutations conferring multidrug resistance during prophylaxis for cytomegalovirus disease. J Infect Dis 1997: 176: 786-789.
68. DREW WL, MINER R, BUSCH DF, et al. Prevention of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991: 163: 716-719.
69. BOIVIN G, ERICE A, CRANE D, et al. Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates form solid organ transplant recipients with CMV viremia after prophylaxis. J Infect Dis 1993: 168: 332-335.
70. KROSGAARD K, BOSEGAARD S, ALDERSHVILE J, et al. Cytomegaloviru infection rate among heart transplant patients in relation to anti-thymocyte immunoglobulin induction therapy. Scand J Infect Dis 1994: 26: 239-247.
71. PORTELA D, PATEL R, LARSON-KELLER J, et al. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation. J Infect Dis 1995: 1771: 1014-1018.
72. LUMBRERAS C, OTERO J, HERRERO J, et al. Ganciclovir prophylaxis decreases frequency and severity of cytomegalovirus disease in seropositive liver transplant recipients treated with OKT3 monoclonal antibodies. Antimicrob Agent Chemother 1993: 37: 2490-2492.
73. TURGEON N, FISHMAN J, BASGOZ N, et al. Effect of oral acyclovir or ganciclovir therapy after pre-emptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy. Transplantation 1998: 66: 1780-1786.
74. STEINMULLER D, NOVIVK A, STREEN S, et al. Intravenous immunoglobulin infusions for theprophylaxis of secondary cytomegalovirus infection. Transplantation 1990: 49: 68-70.
75. STRATTA R, SHAEFFER M, CUSHING K, et al. A randomized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy. Arch Surg 1992: 127: 56-64.